Dr. Michael Hulse ob gyn Hickory Flat Ga. transvaginal mesh complications

601 212 5433
may 20th my fiancee' had the vaginal mesh implanted. may20th evening we were in the emergency room of Cherokee hospital due to a 'mistake' on medications. following week was a complete hell ...bleeding, pain and misery. Surgery was scheduled for 'correction of the mesh ' due to it being too 'tight'. surgery was completed , and she ONLY had to pay for the hospital , not another 'surgeon' fee. Today, she still is in pain along her leg and hip, uses a prescribed cream for what ? and the story continues. Contact with the doc has only resulted in comments..that it will get better. we are in the month of january now, and I cannot see any positive results...anywhere. The bladder problem continues but now we have additional pain along her hip and leg and back. DO NOT do the VAGINAL MESH! Any reputable doctor will not recommend a procedure that results in so many failures, as evidenced by the FDA warnings. She was influenced by Dr. Hulse to continue with the procedure even though my research suggested other wise. feel free to contact me at my email for further 'complications' too personal to publish
contact me if you wish   bobmcalister at gmail

update...feb. 2 2012...been nothing but lot of pain , this time along her hip and stomach. returned to Dr. Michael Hulse for evaluation and received some medication for inflammation...and another encouragement that it is still healing...????   since May ?????   I repeat..do not even consider the vaingal mesh. Matter of fact, if the doctor you are using even suggests the vaginal mesh, GO TO ANOTHER DOCTOR. 

Feb. 5  2012...update
well....she went back to see Dr. Michael Hulse for her stomach pain. He prescribed 4mg tablets of pregnisone...another mistake.  Do not use this if you have high blood pressure..is one of the first warnings ...which he ignored...or made another 'mistake' like prescribing the neurotin thinking it was Advil....obviously, we discontinued the medicin after her blood pressure skyrocketed...avoid this guy or any doctor who recommends the mesh....period.

reviews on Michael Hulse, ob gyn

I refuse to ever see Hulse again!! He is uncaring and only cares about getting you in and out as fast as possible. He doesn't order tests that can prevent other tragedy's. He is rude and very cold. If you want to see a good doctor in that office, ask for Dr. Rush. He did for me what hulse refused to do.

---

Dr. Michael Hulse

July 08, 2009

1

Most uncaring office staff I have ever heard of.

Review by:A Very Upset Mother

Difficult to get information from.Doctor's won't call you back (even when you are having a miscarriage.)Nurses have an attitude that you are bothering them by asking for test results after 3 days, even though was told they would call the next day.My vet treats my dog better...

Surprise!   he has hired someone to post GOOD reviews for him. Steer clear and go to someone with a 5 star rating.

Summary Based on 15 Ratings.

Ease of Appointment

Promptness

Courteous Staff

Accurate Diagnosis

Bedside Manner

Spends Time with Me

Follow Up

FDA on vaginal mesh...Dr. Michael Hulse ob gyn ..avoid !

Per the Food and Drug Administration:

=== === === FDA NEWS RELEASE === === ===
For Release at 12 p.m. on July 13, 2011
From: Karen Riley
FDA: Surgical placement of mesh to repair pelvic organ prolapse poses risks.
Agency says other options may expose women to less risk than transvaginal procedure.

The U.S. Food and Drug Administration today issued an updated safety communication warning health care providers and patients that surgical placement of mesh through the vagina to repair pelvic organ prolapse may expose patients to greater risk than other surgical options.
The safety communication also says that with the exposure to greater risk comes no evidence of greater clinical benefit such as improved quality of life.
Pelvic Organ Prolapse (POP) occurs when the internal structures that support the pelvic organs such as the bladder, uterus and bowel, become so weak or stretched that the organs drop from their normal position and bulge or prolapse into the vagina. While not a life-threatening condition, women withPOP often experience pelvic discomfort, disruption of their sexual, urinary, and defecatory functions, and an overall reduction in their quality of life.
Surgery to repair POP can be performed through the abdomen or transvaginally, through the vagina, using stitches, or with the addition of surgical mesh to reinforce the repair and correct the anatomy.

“There are clear risks associated with the transvaginal placement of mesh to treat POP,” said William Maisel, M.D., M.P.H., deputy director and chief scientist at the FDA’s Center for Devices and Radiological Health. “The FDA is asking surgeons to carefully consider all other treatment options and to make sure that their patients are fully informed of potential complications from surgical mesh. Mesh is a permanent implant — complete removal may not be possible and may not result in complete resolution of complications.”

In 2010, there were at least 100,000 POP repairs that used surgical mesh. About 75,000 of these were transvaginal procedures.

The FDA issued a safety communication in 2008 due to increasing concerns about adverse events associated with the transvaginal placement of mesh. Since then, the number of adverse events has continued to climb. From 2008 to 2010, the FDA received 1,503 adverse event reports associated with mesh used for POP repair, five times as many as the agency received from 2005 to 2007. The reports don’t always differentiate between transvaginal and abdominal procedures.
The most frequently reported complications from surgical mesh used to repair POP include mesh becoming exposed or protruding out of the vaginal tissue (erosion), pain, infection, bleeding, pain during sexual intercourse, organ perforation from surgical tools used in the mesh placement procedure, and urinary problems. Some reports cited the need for additional surgeries or hospitalization to treat complications or to remove the mesh.

The FDA also conducted a review of scientific literature published between 1996 and 2010 comparing mesh surgeries to non-mesh surgeries. The agency review suggests that many patients who undergo transvaginal POP repair with mesh are exposed to additional risks, compared to patients who undergo POP repair with stitches alone. While mesh often corrected anatomy, there was no evidence that mesh provided any greater clinical benefit than non-mesh surgeries.

FDA recommends that health care providers:

• Recognize that in most cases, POP can be treated successfully without mesh.
• Know that surgical mesh is a permanent implant that can make any future surgical repairs more challenging and can put the patient at risk for additional complications and surgeries.
  
• Consider that mesh placed abdominally for POP repair may result in lower rates of mesh complications compared to transvaginal POP surgery with mesh.
  
• Be sure that patients are aware of the risks and benefits of transvaginal POP repair with mesh, and inform patients if mesh is being used.
• 
  The FDA recommends that patients:
  
  
  • Ask the surgeon before surgery about all POP treatment options, including those that do not involve mesh: understand why the surgeon may be recommending treatment of POP with mesh.
    
  • Continue with routine check-ups and follow-up care after surgery. Notify the surgeon if complications develop (persistent vaginal bleeding or discharge, pelvic or groin pain during sex).
    
  • Those who have had POP surgery but don’t know if the surgeon used mesh should find out during their next scheduled visit with their health care provider.
  • The FDA also announced that an outside panel of experts in obstetrics and gynecology will meet on Sept. 8-9, 2011, to discuss the safety and effectiveness of surgical mesh used to treat POP and stress urinary incontinence (SUI), a leakage of urine during physical activity. The panel will discuss the risk of transvaginal POP repair, clinical studies that may be necessary to address risks and benefits of this type of surgery, and FDA’s interim recommendations for health care professionals and patients.
    
    “Input from the clinicians, manufacturers and other experts will help the FDA better understand the safety and effectiveness of surgical mesh for POP and SUI repair, including any changes that would improve our oversight,” Maisel said.
    
    Today’s safety communication is limited to the transvaginal placement of mesh to repair POP. It does not address the safety and effectiveness of mesh used to treat SUI or mesh implanted abdominally.
    
    -=-=-
    FDA Safety Communication: UPDATE on Serious Complications Associated with Transvaginal Placement of Surgical Mesh for Pelvic Organ Prolapse